当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Ashvini S. Kadam, Mukesh P.Ratnaparkhi, Shilpa P. Chaudhary
Much attention has been given in recent years with regard to the transdermal delivery devices. Broadly this system can be considered as single layer and multilayer. Flicks’ first law of diffusion is the principle of drug kinetics. As a substitute for the oral route Transdermal drug delivery enables the avoidance of gastrointestinal absorption, with its associated pit falls of enzymatic and pH associated deactivation. Transdermal delivery has many advantages over conventional modes of drug administrations, it thus avoids hepatic first pass metabolism and improves patient compliance. Its main advantages includes controlled drug release with minimum side effects, improved bioavailability, bypass first pass metabolism and many more. There are factors such as physiochemical as well as biological which affect the bioavailability of transdermal medicament. During the past decade, number of drugs formulated in the patches is hardly increased; there has been little change in the composition of the patch system. Modifications have been mostly limited to refinements of the materials used. The present review article explores the overall study on transdermal drug delivery system (TDDS) which leads to novel drug delivery system (NDDS).